Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02535078
Recruitment Status : Active, not recruiting
First Posted : August 28, 2015
Last Update Posted : January 6, 2021
Sponsor:
Collaborator:
MedImmune LLC
Information provided by (Responsible Party):
Immunocore Ltd

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : August 2022